Amgen Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 02, 2020 / 08:00PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst

Hey, everybody. Welcome to a great afternoon session, continuing on the theme here at the 2020 Jefferies Global Healthcare Conference. I'm Michael Yee, Managing Director, as you know. Really excited to have 2 great representatives of Amgen with us here in our virtual fireside. You know them as familiar faces: Arvind Sood, who heads up all of Investor Relations at Amgen; and fresh out of the virtual ASCO, Executive Vice President of R&D, David Reese there.

Before I get into too much specifics, which I'm sure you're all chomping at the bit to have me ask, I wanted to turn it over briefly to Arvin and David. Maybe make some opening comments about Amgen in the state of 2020, given the COVID situation, coming out of the COVID situation, what does it mean for your guidance? And talk about the state of affairs just operationally for Amgen this year.

Arvind Sood - Amgen Inc. - VP of IR

Excellent. Thank you, Mike, and thanks for inviting us to your conference. So I'll just tee up some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot